Phocas Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-340,541
Closed -$3.41M – 23
2026
Q2
$3.41M Buy
340,541
+145,001
+74% +$1.31M 0.47% 91
2026
Q1
$1.86M Sell
195,540
-55,257
-22% -$429K 0.29% 113
2025
Q4
$1.96M Buy
+250,797
New +$1.81M 0.25% 113

Other funds holding BCRX

Phocas Financial's BCRX Position: Q3 2026 in Review

Phocas Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2026, closing a stake of 340,541 shares — an estimated $3.41M sold.

Phocas Financial first reported a position in BCRX in Q4 2025 and held it in 3 quarters. The position peaked at $3.41M in Q2 2026. 241 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Phocas Financial reported no remaining BioCryst Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 340,541 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $3.41M.
  • Phocas Financial first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Phocas Financial's BioCryst Pharmaceuticals position peaked at $3.41M in Q2 2026.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.